Lipocine (LPCN) Share-based Compensation Growth (1y) (2013 - 2025)
Lipocine (LPCN) Share-based Compensation Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -7.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -8.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -22.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 11.71% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -4.01% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 127.07% |
| Jun 30, 2025 | -36.24% |
| Mar 31, 2025 | -28.50% |
| Dec 31, 2024 | -35.13% |
| Sep 30, 2024 | -31.75% |
| Jun 30, 2024 | -38.02% |
| Mar 31, 2024 | -44.21% |
| Dec 31, 2023 | -7.09% |
| Sep 30, 2023 | -1.33% |
| Jun 30, 2023 | 17.86% |
| Mar 31, 2023 | 4.08% |
| Dec 31, 2022 | 6.76% |
| Sep 30, 2022 | 3.37% |
| Jun 30, 2022 | -4.76% |
| Mar 31, 2022 | 15.56% |
| Dec 31, 2021 | -40.82% |
| Sep 30, 2021 | -55.97% |
| Jun 30, 2021 | -68.39% |
| Mar 31, 2021 | -54.02% |
| Dec 31, 2020 | 2.74% |